title: Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.
abstract: OBJECTIVE
  A phase II trial was performed to evaluate the safety and efficacy of rituximab, a chimeric anti-CD20 monoclonal antibody, in patients with bulky (> 10-cm lesion) relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma (NHL).
  
  
  METHODS
  Thirty-one patients received intravenous infusions of rituximab 375 mg/m(2) weekly for four doses. All patients had at least one prior therapy (median, three; range, one to 13) and had progressive disease at study entry. Patients were a median of 4 years from diagnosis.
  
  
  RESULTS
  No patient had treatment discontinued because of an adverse event. No patient developed human antichimeric antibody. The overall response rate in 28 assessable patients was 43% with a median time to progression of 8.1 months (range, 4.5 to 18.6+ months) and median duration of response of 5.9 months (range, 2.8 to 12.1+ months). The average decrease in lesion size in patients who achieved a partial response was 76%, and patients with stable disease had a decrease in average lesion size of 26%. Median serum antibody concentration was higher in responders compared with nonresponders, and a negative correlation was shown between antibody concentration and tumor bulk at baseline.
  
  
  CONCLUSIONS
  Rituximab single-agent outpatient therapy is safe and shows significant clinical activity in patients with bulky relapsed or refractory low-grade or follicular B-cell NHL.
authors.affiliation: Stanford University Medical Center, Stanford, CA, USA. davist@ctep.nci.nih.gov
authors.forename: T A
authors.initials: TA
authors.lastname: Davis
authors.forename: C A
authors.initials: CA
authors.lastname: White
authors.forename: A J
authors.initials: AJ
authors.lastname: Grillo-López
authors.forename: W S
authors.initials: WS
authors.lastname: Velásquez
authors.forename: B
authors.initials: B
authors.lastname: Link
authors.forename: D G
authors.initials: DG
authors.lastname: Maloney
authors.forename: R O
authors.initials: RO
authors.lastname: Dillman
authors.forename: M E
authors.initials: ME
authors.lastname: Williams
authors.forename: A
authors.initials: A
authors.lastname: Mohrbacher
authors.forename: R
authors.initials: R
authors.lastname: Weaver
authors.forename: S
authors.initials: S
authors.lastname: Dowden
authors.forename: R
authors.initials: R
authors.lastname: Levy
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006403:Hematologic Tests; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab